Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome

被引:46
作者
Avcin, T.
Silverman, E. D.
机构
[1] Univ Ljubljana, Med Ctr, Univ Childrens Hosp, Dept Allergol, SL-1525 Ljubljana, Slovenia
[2] Univ Ljubljana, Med Ctr, Univ Childrens Hosp, Dept Rheumatol, Ljubljana 61000, Slovenia
[3] Univ Ljubljana, Med Ctr, Univ Childrens Hosp, Dept Clin Immunol, Ljubljana 61000, Slovenia
[4] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada
[5] Univ Toronto, Hosp Sick Children, Dept Immunol, Div Rheumatol, Toronto, ON M5G 1X8, Canada
关键词
D O I
10.1177/0961203307079036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The anti phospholipid syndrome (APS) is recognized increasingly as the most common acquired hypercoagulation state of autoimmune etiology and may occur as an isolated clinical entity (primary APS) or in association with an underlying systemic disease, particularly systemic lupus erythematosus (SLE). The major differences between pediatric and adult APS include absence of common acquired risk factors for thrombosis, absence of pregnancy-related morbidity, increased incidence of infection-induced antibodies, differences in CM-Off values for determination of aPL and specific factors regarding long-term therapy in children. APS in children has been largely reported in patients with arterial or venous thromboses and less frequently in association with neurological or hematological manifestations. The presence of aPL in pediatric SLE can modify the disease expression and may be an important predictor of the development of irreversible organ damage. Two recently established international registries of neonates and children with APS provide a good opportunity to conduct large, prospective studies on the clinical significance of aPL and long-term outcome of pediatric APS.
引用
收藏
页码:627 / 633
页数:7
相关论文
共 72 条
[41]   Antiphospholipid syndrome: multiple mechanisms [J].
Mackworth-Young, CG .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 136 (03) :393-401
[42]   Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus [J].
Male, C ;
Foulon, D ;
Hoogendoorn, H ;
Vegh, P ;
Silverman, E ;
David, M ;
Mitchell, L .
BLOOD, 2005, 106 (13) :4152-4158
[43]   Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus [J].
Male, C ;
Mitchell, L ;
Julian, J ;
Vegh, P ;
Joshua, P ;
Adams, M ;
David, M ;
Andrew, ME .
BLOOD, 2001, 97 (04) :844-849
[44]   LUPUS ANTICOAGULANT IN CHILDREN WITH THROMBOSIS [J].
MANCOJOHNSON, MJ ;
NUSS, R .
AMERICAN JOURNAL OF HEMATOLOGY, 1995, 48 (04) :240-243
[45]   Antiphospholipid antibodies in pediatric lupus nephritis [J].
Massengill, SF ;
Hedrick, C ;
Ayoub, EM ;
Sleasman, JW ;
Kao, KJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (03) :355-361
[46]   THE USE OF AN ANTI-BETA(2)-GLYCOPROTEIN-I ASSAY FOR DISCRIMINATION BETWEEN ANTICARDIOLIPIN ANTIBODIES ASSOCIATED WITH INFECTION AND INCREASED RISK OF THROMBOSIS [J].
MCNALLY, T ;
PURDY, G ;
MACKIE, IJ ;
MACHIN, SJ ;
ISENBERG, DA .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) :471-473
[47]   Pathogenic mechanisms mediating antiphospholipid syndrome [J].
Meroni, PL ;
Riboldi, P .
CURRENT OPINION IN RHEUMATOLOGY, 2001, 13 (05) :377-382
[48]   Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort [J].
Mikdashi, J ;
Handwerger, B .
RHEUMATOLOGY, 2004, 43 (12) :1555-1560
[49]   International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [J].
Miyakis, S ;
Lockshin, MD ;
Atsumi, T ;
Branch, DW ;
Brey, RL ;
Cervera, R ;
Derksen, RHWM ;
De Groot, PG ;
Koike, T ;
Meroni, PL ;
Reber, G ;
Shoenfeld, Y ;
Tincani, A ;
Vlachoyiannopoulos, PG ;
Krilis, SA .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :295-306
[50]  
MOLTA C, 1993, PEDIATRICS, V92, P849